History of Vaccines in Poultry

Executive Summary

The history of vaccines in poultry stretches from Louis Pasteur's accidental discovery of attenuation in 1879 to the frontier of mRNA nanoparticle technology in the 2020s. Over nearly 150 years, poultry vaccination evolved from crude live-pathogen preparations to multi-valent recombinant vector vaccines administered to billions of embryos before they even hatch. This transformation not only saved the poultry industry from potentially catastrophic disease losses but also produced some of the most consequential vaccine science in all of veterinary medicine — including the world's first successful cancer vaccine. Understanding this history illuminates the deep interplay between scientific innovation, industry need, regulatory oversight, and public health imperative.

The Pre-Vaccine Era: Disease as a Constant Threat

Before the advent of modern vaccines, infectious diseases were the most destructive force facing poultry producers worldwide. In the absence of effective prevention, epizootics periodically wiped out entire flocks with devastating efficiency. Newcastle disease was so lethal in early outbreaks that it reportedly killed all domestic chickens in northwest regions in 1898. Fowlpox, described as early as 1844 by Heusinger, was one of the first avian diseases formally documented due to its characteristic external skin lesions. Marek's disease "almost devastated the poultry industry in the 1960s" before any vaccine was developed.[^1][^2][^3]

The economic and food-security dimensions of poultry disease drove government investment in veterinary science earlier than in almost any other livestock sector. In the United States, the Bureau of Animal Industry (BAI) was established within the Department of Agriculture in 1884 in response to extensive disease losses. The passage of the Virus-Serum-Toxin Act in 1913 gave the USDA authority to regulate veterinary biologics crossing state lines and marked the formal beginning of the regulated poultry vaccine industry. By 1913, only a small number of establishments produced products for the poultry industry.[^4][^5]

1. The Foundational Breakthrough: Pasteur and Fowl Cholera (1879–1880s)

The story of poultry vaccines begins not in a poultry house but in Louis Pasteur's Paris laboratory. Pasteur had been studying fowl cholera (Pasteurella multocida) by injecting chickens with live bacteria and recording the fatal progression of the disease. According to accounts preserved by the History of Vaccines project, an assistant forgot to carry out an inoculation before a holiday and left bacterial cultures exposed to air for a month. When the assistant finally inoculated chickens with the aged culture, the birds showed only mild signs of illness and survived. Crucially, when those same chickens were subsequently challenged with fresh, virulent bacteria, they did not fall ill.[^6]

Pasteur reasoned that prolonged exposure to oxygen had weakened — attenuated — the bacteria's virulence while preserving its capacity to stimulate immunity. He formalized his development of the fowl cholera vaccine through aging in contact with oxygen in the air, producing a functioning vaccine by 1878–1879. This discovery was seismic. It established the principle of attenuation — the deliberate weakening of a pathogen to produce a safe but immunogenic vaccine — and laid the conceptual foundation for almost every live vaccine that followed over the next century and a half. The first live attenuated poultry vaccine had been born, though it would be decades before the full implications of Pasteur's method were realized industrially.[^7][^8]

2. Early 20th Century: Fowlpox and the First Licensed Vaccines (1900s–1930s)

Following Pasteur's work, the early 20th century saw the first practical vaccine programs move into the field. Fowlpox was among the earliest targets. Early vaccination attempts against fowlpox used crude injections of ground scab material dissolved in saline solution to provoke immunity. Beginning in the 1920s, this approach was replaced by more refined techniques: vaccine was applied through superficial stabs to the skin or directly into feather follicles. By the 1940s, a live-virus fowlpox vaccine grown in chicken embryos — then a relatively new propagation method — was commercially available, packaged with a diluent and an applicator brush or stick vaccinator.[^5]

The Smithsonian Institution preserves examples of early American fowlpox vaccines, including a Lederle Laboratories product from around 1941 and an American Cyanamid Company vaccine from around 1959. These specimens illustrate the progression from the "follicle method" (brushing vaccine into plucked feather follicles) to the "stick method" (dipping a two-pronged needle in vaccine and jabbing through the wing web) — an early illustration of how delivery technology evolved alongside the biological product itself.[^5]

The first USDA license for any poultry biological product was issued in 1918 to the University of California, Berkeley, for fowlpox vaccine. This regulatory milestone reflected a growing recognition that poultry vaccines needed to meet standards of purity, safety, and potency. Subsequent licensed products came slowly: infectious laryngotracheitis (ILT) vaccine was licensed in 1933, and pigeonpox vaccine in 1939.[^4]

Infectious Laryngotracheitis

Infectious laryngotracheitis (ILT), a highly contagious herpesvirus respiratory disease of chickens, became a major focus of early vaccine development. Conventional attenuated ILT vaccines were produced through continuous passages of the virus in chicken embryos and cell cultures. These modified-live vaccines were the primary tool against ILT for many decades, though they carried a significant drawback: vaccinated birds could become permanent latent carriers of the virus, capable of spreading infection to unvaccinated flocks. This characteristic would eventually drive the development of safer recombinant alternatives in the 2000s.[^9][^10]

Infectious Bronchitis

The first observed case of infectious bronchitis (IB) in the United States was reported in North Dakota in 1930, with the first documented description published by Schalk and Hawn in 1931. The first IB isolate was made by Beaudette and Hudson in 1937. Live attenuated IB vaccines produced by passage in embryonated chicken eggs were introduced in the 1950s, followed by inactivated vaccines in later decades. The Connecticut variant, which became one of the most widely used vaccine strains, was isolated in 1951. Licensing of the first bronchitis vaccine in the United States followed in 1953.[^11][^12][^13][^4]

3. Newcastle Disease: The Vaccine That Changed the Industry (1930s–1960s)

Newcastle disease (ND) became one of the defining challenges of mid-20th-century poultry science. First identified in 1926 in Indonesia and in England in 1927, it was named after Newcastle-upon-Tyne by scientist Doyle following an early outbreak. The disease's capacity to spread rapidly through flocks — infecting birds in 109 countries over five years according to later OIE data — made vaccine development an urgent priority.[^1]

The coordinated research program that led to modern Newcastle disease vaccines was shaped at a conference of poultry pathologists held in Baltimore in November 1946. The regulatory history of Newcastle vaccines in the United States tracks in detail the rapid progression of the field:[^14]

• An inactivated Newcastle vaccine was licensed in 1946[^4]
• The Roakin strain (a mesogenic vaccine) was licensed in 1948[^4]
• The B1 strain (Blacksburg/Hitchner strain), a lentogenic American strain of low virulence, was licensed in 1950[^15][^4]
• The LaSota strain, isolated from the farm of Adam LaSota in Westwood, New Jersey, where chicks were submitted for examination in February 1946, was licensed in 1952[^15]

The Hitchner B1 and LaSota strains became the backbone of Newcastle disease vaccination programs worldwide and remain in wide use today. The B1 strain and LaSota strain were both classified as lentogenic (low virulence) — a crucial property that allowed them to stimulate immunity with minimal adverse reactions. LaSota, somewhat more reactive than B1, was typically used as a booster in flocks already primed with the milder B1.[^16][^17]

A significant chapter in Newcastle vaccine history was the development of thermostable vaccine strains for village chickens in developing countries. Standard Newcastle vaccines deteriorated within one to two hours at room temperature, making them impractical for remote or resource-limited settings. The V4 avirulent strain, recognized in Australia after 1966 when it was demonstrated that avirulent strains were endemic in local flocks, became an important candidate for village chicken vaccination programs. The I-2 thermostable Newcastle disease vaccine, which remains viable without strict cold-chain maintenance during short transport periods, was developed specifically for local and regional production for village chicken programs in developing countries. These thermostable vaccines could maintain viability through transportation wrapped in damp cloth for evaporative cooling, a low-technology solution to a major logistics challenge.[^18][^16]

4. The Marek's Disease Revolution: The First Cancer Vaccine (1960s–1970s)

Perhaps the most extraordinary chapter in the history of poultry vaccines — and indeed in the broader history of vaccinology — is the story of Marek's disease (MD) vaccination. Marek's disease, caused by a highly cell-associated herpesvirus (MDV), produces visceral lymphomas, neural lesions, and paralysis in chickens. By the 1960s, increasingly virulent strains were causing losses so severe they threatened the viability of the commercial poultry industry.[^2]

The breakthrough came with the identification of MDV itself. In 1967, Churchill and Biggs of the Houghton Poultry Research Station (HPRS) in England successfully isolated and identified the agent of Marek's disease as a herpesvirus — a discovery published in Nature (Churchill AE, Biggs PM, 1967). Within only two years, the first successful vaccines were developed, setting a speed record for going from pathogen identification to commercial vaccine that has rarely been matched.[^19][^20]

Three parallel vaccine development programs emerged almost simultaneously:[^21]

1. Biggs and associates at HPRS (England) attenuated the HPRS-16 MDV strain by passaging it in chick kidney cells, producing HPRS-16/Att, which became the first commercially available Marek's vaccine — although it was soon superseded.[^21]

2. Witter and associates at the USDA Regional Poultry Research Laboratory in East Lansing, Michigan developed the FC126 strain of herpesvirus of turkeys (HVT). Ironically, Kawamura and colleagues had isolated a herpesvirus from turkey kidney cell cultures in 1969 but never realized its vaccine potential; the USDA team recognized that this turkey herpesvirus, while causing no disease in chickens, could cross-protect them against MD. The HVT/FC126 vaccine became the most widely used Marek's vaccine globally.[^21]

3. Rispens of the Central Veterinary Institute (CVI) in The Netherlands developed a third approach using an attenuated naturally nononcogenic MDV strain.[^21]

Marek's disease vaccines have been in almost universal use since the early 1970s and constituted the first effective practical means for the control of any neoplastic (cancer) disease in any species — humans or animals. This achievement was a landmark in the history of medicine, not merely of veterinary science. Vaccination of newly-hatched chicks with live cell-associated vaccines became standard practice worldwide, and commercial broiler and layer operations adopted it as a routine hatchery procedure.[^22][^2]

However, the story did not end in triumph. During the late 1970s, HVT alone was no longer fully protective against some new emerging field strains. The MDV was evolving — a phenomenon later termed "Marek's disease virus evolution under vaccine pressure" — and successively more virulent pathotypes (termed "vv" for very virulent, and "vv+" for very virulent plus) emerged in the 1980s and 1990s. This response prompted the development of bivalent and later trivalent vaccines combining HVT with Rispens' strain or with other MDV serotypes. The cycle of virulence evolution in MDV in response to vaccination pressure became one of the most studied and debated phenomena in vaccinology, raising fundamental questions about whether the leaky, non-sterilizing nature of Marek's vaccines was inadvertently "ratcheting up" virus virulence.[^2][^21]

5. Infectious Bursal Disease (Gumboro): A Global Scourge and Its Vaccines (1960s–1990s)

Infectious bursal disease (IBD), also called Gumboro disease after its discovery site, was first identified in Gumboro, Delaware, in 1962. Caused by infectious bursal disease virus (IBDV), a double-stranded RNA virus, it attacks the bursa of Fabricius in young chickens, destroying a primary organ of the immune system and leaving birds severely immunocompromised. The disease spread globally with remarkable speed — reaching Pakistan by 1971 and causing economic losses across Asia, Europe, and the Americas.[^23][^24]

Live attenuated vaccines against IBDV became the most important and effective tools for preventing the disease since its appearance and are still commonly used worldwide. However, IBD vaccination presented a unique challenge: maternal derived antibodies (MDA) transferred from vaccinated breeder hens to chicks via the yolk could neutralize live-attenuated vaccine virus before it could stimulate the chick's own immunity, leaving chicks unprotected as MDA titers declined.[^25]

To navigate this timing problem, the industry developed increasingly aggressive ("hot") intermediate-plus live attenuated strains capable of breaking through MDA, at the cost of some degree of bursal damage. This eventually led to outbreaks of vaccine-induced immunosuppression. The use of immune complex vaccines — consisting of a mixture of live-attenuated IBD virus pre-complexed with IBD-specific antibodies — began in approximately the 1990s as a way to allow the vaccine to evade MDA and establish replication at the appropriate time. By the 2000s and 2010s, recombinant HVT-IBD vector vaccines administered in ovo emerged as a dominant solution that could be given at the hatchery and provide persistent protection, circumventing the MDA problem entirely by relying on cell-mediated immunity through the HVT vector. By approximately 2008, the Brazilian poultry industry began intensive use of rHVT-IBD vaccines — a practice that then spread to dozens of countries and billions of birds.[^26][^25]

A further complication was the emergence of very virulent IBDV strains in Europe in the late 1980s and variant strains in the United States, both of which showed reduced susceptibility to vaccines developed against classical IBDV. This required the development of new vaccines and vaccination programs matched to the specific serotype and variant prevalent in each region.[^27]

6. Coccidiosis Vaccines: Fifty Years of Protecting the Gut (1952–Present)

Coccidiosis, caused by Eimeria protozoan parasites, is among the most economically significant diseases in the poultry industry globally. The world's first commercially successful anticoccidial vaccine was developed by Professor S.A. Edgar of Auburn University and first marketed by Dorn and Mitchell, Inc. in 1952, under the trade name CocciVac. This pioneering product contained live, non-attenuated Eimeria tenella oocysts — a bold approach that relied on controlled exposure to establish immunity without severe disease.[^28]

Through several reformulations incorporating various Eimeria species, CocciVac expanded its coverage, and a turkey formulation was also developed. A similar product, Immucox, was developed by Dr. E.-H. Lee and first marketed in Canada in 1985 by Vetech Laboratories.[^28]

The development of attenuated anticoccidial vaccines followed a key 1974 publication by Dr. T.K. Jeffers of Hess and Clark, Inc., who discovered precocious lines of coccidia — strains that completed their life cycles more rapidly and with less pathogenic damage. Though Jeffers was unable to commercialize his discovery, Dr. M.W. Shirley and colleagues at the Houghton Poultry Research Station in the United Kingdom used these precocious lines to develop the first attenuated anticoccidial vaccine. Commercially developed by Glaxo Animal Health Ltd. and then Pitman-Moore, Inc., it was launched in The Netherlands in 1989 under the trade name Paracox.[^28]

A third attenuation approach — embryo adaptation — was pioneered by Dr. P.L. Long, originally at HPRS and later at the University of Georgia, reported in 1972. An embryo-adapted line of E. tenella combined with precocious lines produced a series of attenuated chicken vaccines under the trade name Livacox, developed in the Czech Republic and launched by Biopharm in 1992. All subsequent commercially available live anticoccidial vaccines have been based on the scientific principles established by CocciVac, Paracox, or Livacox.[^28]

7. Avian Influenza Vaccines: Racing Against a Pandemic Threat (1997–Present)

Avian influenza (AI) posed a fundamentally different challenge to vaccine developers: a rapidly mutating virus with pandemic implications for both animals and humans. The first clinical H5N1 avian influenza respiratory illness in humans occurred in Hong Kong in 1997 during a poultry outbreak. This event galvanized international attention and initiated serious investment in avian influenza vaccines for poultry.[^29]

Zoetis (then part of Pfizer Animal Health) began working on HPAI vaccines in 2001–02 when outbreaks occurred in Southeast Asia. The USDA's National Poultry Research Center developed an emergency avian influenza vaccine within just two weeks in response to the detection of new HPAI viruses (H5N8 and H5N2) in December 2014. The 2015 outbreak spread across 21 US states, resulting in the loss of 7.5 million turkeys and 42.1 million chickens at a cost of more than $950 million.[^30][^31]

On the regulatory front, the US FDA approved the first nonadjuvant subvirion H5N1 avian influenza vaccine in 2007. An oil-in-water emulsion (AS03)-adjuvanted subvirion H5N1 vaccine was approved for prepandemic use in the European Union in 2008 and the United States in 2013. In February 2025, Zoetis received a conditional USDA license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, labeled for use in chickens — a direct response to the ongoing HPAI crisis in which more than 150 million birds in the United States had been affected since February 2022.[^32][^31]

Newcastle disease virus (NDV) has also been engineered as a vector to produce vaccines against H5 and H7 subtypes of avian influenza and is commercially available in some countries. These vectored AI vaccines offer the critical DIVA (Differentiating Infected from Vaccinated Animals) property — vaccinating birds against a single H5 hemagglutinin protein does not produce antibodies to the full array of AI viral components, allowing serological surveillance to continue during vaccination campaigns.[^8][^26]

8. The In-Ovo Vaccination Revolution (1980s–1990s)

One of the most important technological advances in poultry vaccine delivery was the development of in-ovo vaccination — administering vaccines directly into the developing egg before hatching. ARS poultry scientists in East Lansing, Michigan, were the first to develop a method to vaccinate chicken embryos inside the eggshell against Marek's disease in the 1980s. This work laid the foundation for a transformative industry partnership.[^33]

Embrex, Inc., of Research Triangle Park, North Carolina, obtained an exclusive license to the ARS egg-injection technology and in 1987 entered a cooperative research and development agreement (CRADA) with ARS — the first CRADA between any private company and a government laboratory under the Federal Technology Transfer Act of 1986. Embrex introduced an automated system in 1992, capable of inoculating up to 45,000 eggs per hour. Tyson Foods was the first commercial producer to install it in a hatchery.[^33]

The first poultry vaccine available for in-ovo administration worldwide, including Canada, was for Marek's disease in the early 1990s. By the late 1990s, more than 80% of the US broiler industry had converted to in-ovo vaccination for Marek's disease control. Embrex and Tyson Foods agreed to use the technology to inject more than 2.5 billion chickens per year, with ARS-estimated industry savings of approximately $70 million annually.[^34][^35][^33]

In-ovo vaccination transformed hatchery management. By vaccinating the embryo before the bird even hatches, the window of vulnerability between hatch and first post-hatch injection is eliminated. The technique also allows automation of what was previously an extremely labor-intensive process. Adoption rates for in-ovo broiler vaccination reached more than 90% in the United States, approximately 80% in Canada, Spain, and Brazil, and continue to grow in Asia and Africa.[^34]

9. Recombinant Vector Vaccines: A New Paradigm (1985–Present)

The application of recombinant DNA technology to poultry vaccine development beginning in the 1980s inaugurated a new era of precision and safety. An application for one of the first recombinant vaccines for poultry — a Vectorvax™ fowlpox-vectored vaccine expressing an immunogenic Newcastle disease protein — was filed with the US Patent and Trademark Office in 1985 by Syntro Animal Health, Inc., though it was never commercialized.[^26]

The first commercially produced recombinant poultry vaccine was a fowlpox-vectored vaccine against ILT (rFP-LT), introduced by Ceva-Biomune in or around 2006. Approximately a year later, Merck Sharpe and Dohme introduced the first herpesvirus of turkey (HVT)-vectored vaccine against ILT (rHVT-LT). Both vaccines were rapidly adopted by broiler producers through in-ovo administration, replacing the older CEO (chicken embryo origin) ILT vaccines that had the drawback of creating latent carrier birds.[^26]

The advantages of recombinant vector vaccines over conventional live vaccines include:

• No reversion to virulence: Only a single protein is expressed from the vector, eliminating the possibility of the vaccine strain reverting to a pathogenic form
• Multivalency: The HVT vector simultaneously protects against Marek's disease while expressing antigens from other pathogens, providing dual or triple protection in a single vaccination event
• MDA evasion: Cell-associated HVT vaccines are resistant to inhibition by maternal derived antibodies, enabling reliable early protection
• Hatchery applicability: Recombinant vaccines are convenient, safe, and suitable for automated in-ovo or day-of-hatch administration under controlled hatchery conditions[^36][^26]

Using HVT and fowlpox virus vectors, more than 15 recombinant viral vector vaccines against Newcastle disease, ILT, IBD, avian influenza, and Mycoplasma gallisepticum have been developed and are commercially available today. Trivalent HVT-based vaccines, licensed for in-ovo or day-of-age vaccination, combine the HVT vector with IBDV and NDV or ILTV antigens in a single injection. These products represent a dramatic compression of the vaccination schedule, protecting against three diseases with a single dose.[^8][^36]

10. Salmonella Vaccines: Food Safety at the Flock Level

Unlike the viral diseases that primarily threatened flock health and production economics, Salmonella vaccination in poultry is fundamentally driven by public health concerns — specifically, reducing the risk of Salmonella enteritidis and S. typhimurium contaminating eggs and poultry meat and causing human foodborne illness. The development of Salmonella vaccines for poultry was therefore shaped heavily by government food safety policy, particularly in the European Union, where mandatory reduction targets for these serovars in breeding and laying flocks drove widespread vaccine adoption.[^37]

Both live-attenuated and inactivated Salmonella vaccines have been developed and used in commercial layer flocks. Inactivated vaccines are generally preferred for laying hens to reduce the risk of vaccine strain transmission to eggs. Live vaccines can be used earlier in a bird's life to reduce intestinal colonization. European Food Safety Authority guidance concluded that if a control programme targets S. enteritidis and S. typhimurium in breeders and laying hens and flock prevalence is high, vaccination is useful in reducing shedding and egg contamination.[^37]

Advances in genetic engineering have enabled the development of defined deletion mutant strains of Salmonella — strains with specific genes removed to eliminate antimicrobial resistance markers and improve stability — that are being explored as next-generation vaccine candidates.[^38]

11. Regulatory Framework: Building Trust in Poultry Biologics

The evolution of poultry vaccines cannot be separated from the evolution of regulatory oversight. In the United States, the Virus-Serum-Toxin Act of 1913 was passed largely because of public concern over contaminated imports and fraudulent hog cholera products. Federal regulation was initially carried out by USDA veterinary field inspectors stationed in commercial biologics manufacturing establishments. In 1961, a central testing laboratory was established at the National Animal Disease Laboratory in Ames, Iowa, shifting regulatory emphasis from plant inspection to standardized product testing.[^39]

The passage of an amendment to the Virus-Serum-Toxin Act in 1985 extended USDA authority to regulate all veterinary biological products in intrastate commerce as well, completing a framework that covers all commercial poultry vaccine production in the country. By the end of the 1960s, the USDA had established basic purity and safety standards for poultry biologics and licensed products to address the major poultry diseases of concern at that time.[^40][^41]

As new diseases emerged and poultry husbandry practices changed in the 1970s through 1990s, USDA Veterinary Services employed special and conditional licensing procedures to shorten the time to license products needed to address emerging disease problems. Vaccines for infectious bronchitis, bursal disease, fowl cholera, duck virus enteritis, and avian influenza were all rapidly licensed under this system. Changes in labeling and packaging requirements addressed changing vaccination practices, including permitting diluents to be shipped separately from lyophilized products — first for Marek's disease vaccine and later for others recommended for mass administration in drinking water.[^40]

12. Modern Vaccine Technologies: From Subunit to mRNA (2000s–Present)

The turn of the 21st century brought a cascade of technological advances in vaccine science that are now beginning to transform poultry vaccinology.

Subunit and Virus-Like Particle Vaccines

Recombinant subunit vaccines use specifically expressed proteins from pathogens as antigens, eliminating all other viral material. Research has demonstrated efficacy of recombinant subunit vaccines against IBDV, Eimeria species, chicken infectious anemia, and avian leukosis virus, though commercial availability in poultry remains limited compared to viral vector vaccines. Adjuvant systems — substances added to enhance immunogenicity — have become critical companions to subunit vaccines, stimulating innate immune responses and sustaining antigen depots.[^8]

DNA Vaccines

DNA vaccine development for poultry showed early promise: in 1999, immunization of chickens with plasmid DNA encoding IBDV antigen demonstrated protective efficacy against challenge. Hemagglutinin DNA vaccines for H5N8 avian influenza conferred complete protection against homologous virus and significant cross-protection against antigenically distinct H5N2 variants. DNA vaccines have been demonstrated efficacious against ILT virus, Eimeria spp., IB virus, and NDV in experimental settings. However, as of 2024, no DNA vaccines have been formally authorized for commercial use in poultry.[^8]

mRNA Vaccines

The COVID-19 pandemic accelerated global investment in mRNA vaccine platforms and generated direct spillover into poultry vaccinology. Researchers from the US National Poultry Research Center successfully designed plasmid-based DNA templates holding stable mRNA constructs targeting infectious bronchitis virus (IBV) and infectious laryngotracheitis virus as part of research completed for USPOULTRY. This type of vaccine could avoid the risk of reversion to virulence, interference from maternal antibodies, and complications from multiple vaccine virus interactions associated with current live or recombinant vaccines.[^42]

At the University of Connecticut, researchers demonstrated that a novel protein-based nanoparticle (derived from modified bovine serum albumin) could stabilize and deliver mRNA IBV vaccine, with vaccinated chickens showing a 1,000-fold increase in antibodies against IBV compared to unvaccinated controls. The team is evaluating spray delivery as an alternative to individual injection, which would allow large-flock vaccination without animal handling stress. The UConn team's work illustrates how the mRNA platform offers a pathway to "plug in" any pathogen's genetic code for rapid, adaptable vaccine development.[^43]

Key Milestones Timeline

Challenges, Controversies, and Future Directions

The Marek's Disease "Evolution Problem"

The phenomenon of progressively more virulent MDV field strains emerging under the selective pressure of imperfect (non-sterilizing) vaccination is one of the most concerning patterns in poultry vaccine history. Because Marek's disease vaccines prevent clinical disease but not infection or viral shedding, vaccinated birds can still be infected and transmit MDV — potentially allowing more virulent strains to spread in fully vaccinated populations. This dynamic has been studied extensively as a potential model for the evolution of vaccine-escape pathogens across both veterinary and human medicine.[^2]

Antigenic Diversity and Variant Strains

Infectious bronchitis virus shows extraordinary serotypic diversity, with dozens of genotypes circulating globally — many of which cross-protect poorly against each other. New IBV variants continuously emerge through mutations and recombination, requiring ongoing surveillance and vaccine updating. A "targeted attenuation" approach under investigation at the Pirbright Institute uses specific mutations in the non-structural protein nsp3 to attenuate the virus in a more predictable and adaptable manner than classical serial passage.[^44]

Avian Influenza: A Geopolitical Challenge

The use of poultry vaccines against HPAI remains contentious in international trade law, because vaccinated birds can carry and shed virus without clinical signs, complicating disease surveillance. The DIVA (Differentiating Infected from Vaccinated Animals) strategy, enabled by modern vectored AI vaccines that express only a single viral protein, is a critical tool for reconciling vaccination with trade requirements. As HPAI H5N1 continues to spread across wild bird and domestic poultry populations worldwide in the 2020s, pressure to adopt routine poultry vaccination against HPAI is intensifying in multiple countries.[^31][^8]

The Promise of Third-Generation Platforms

mRNA and DNA vaccine platforms offer the possibility of ultra-rapid development — generating candidate vaccines from genome sequences within days — with no risk of reversion to virulence, no requirement for high-biosafety-level manufacturing, and the potential for simplified mass delivery through spray or in-ovo administration. While no mRNA poultry vaccine has yet been commercially licensed, the convergence of COVID-19-era mRNA manufacturing investment with poultry industry need suggests that commercial launch is a near-term possibility rather than a distant aspiration.[^42][^43]

Conclusion

The history of vaccines in poultry is a story of continuous innovation driven by unrelenting disease pressure, a growing global demand for affordable protein, and the profound interdependence of animal health, public health, and food security. From Pasteur's accidental discovery of attenuation in a Paris laboratory to automated machines injecting hundreds of thousands of embryos per hour with multivalent recombinant vaccines, each era has built upon the insights of the last. The first cancer vaccine in history was developed not for humans, but for chickens. Technologies pioneered for poultry in-ovo vaccination became models for large-scale hatchery biomanufacturing. The poultry industry's adoption of recombinant vector technology drove commercial refinement of viral vector platforms that now serve as templates across veterinary medicine. As the industry faces emerging HPAI threats, growing antibiotic resistance, and the demands of a population expected to reach 10 billion people, the next generation of poultry vaccines — thermostable, multivalent, mRNA-based, nanoparticle-delivered — will be built on this extraordinary foundation.

References

1. Vaccine Development for Newcastle Disease Virus in Poultry - The vaccine construct with higher antigenicity could induce stronger immune primary and secondary im...

2. Use of Marek's disease vaccines: could they be driving the virus to ... - MD almost devastated the poultry industry in the 1960s but the disease was brought under control aft...

3. [PDF] foWl poX - Ceva Fjer - fp is one of the earliest described avian diseases, due its characteristic, easily-identifiable exte...

4. Early history of regulatory requirements for poultry ... - Congress passed the Virus-Serum-Toxin Act in 1913, giving the U.S. Department of Agriculture (USDA) ...

5. Veterinary Vaccines and Serums - Early 20th-century vaccination attempts used injections of ground scab material in saline solution t...

6. Louis Pasteur, ForMemRS | History of Vaccines - History of Vaccines is an educational resource by the College of Physicians of Philadelphia, one of ...

7. The final years 1877-1887 | - Institut Pasteur - Edward jenner invented vaccination, louis pasteur invented vaccinesIn 1877 he closely studied infect...

8. Advances in Poultry Vaccines: Leveraging Biotechnology for ... - PMC - The development of inactivated-whole cell vaccines started in the late 18th century by killing the p...

9. [PDF] Poultry Health Basics: Infectious Laryngotracheitis (ILT) - Most ILT-vaccinated exhibition birds are vaccinated with the type of vaccine that results in the bir...

10. Endemic Poultry Viral Diseases Research - Publication : USDA ARS - Conventional attenuated ILT vaccines, obtained by continuous passages in chicken embryos and tissue ...

11. Severe acute respiratory syndrome vaccine development - PubMed - Live attenuated (by passage in chicken embryonated eggs) IBV strains were introduced as vaccines in ...

12. Infectious Bronchitis in Commercial Chickens - The first observed case of infectious bronchitis in the United States was reported in North Dakota i...

13. Infectious Bronchitis: Key points about vaccination | The Poultry Site - The first IB isolate in the Netherlands was in 1956, this virus isolate was used, through a number o...

14. The Development of Newcastle Disease Vaccines - ScienceDirect.com - The present coordinated research program on this disease was developed at a conference of poultry pa...

15. Newcastle Vaccine strains - Poultry Med - LaSota strain: the strain had been isolated from the farm of Adam LaSota in Westwood, Bergen County,...

16. 1. Newcastle disease vaccines: an overview - The I-2 Newcastle disease vaccine has been developed for local or regional production and use in con...

17. Newcastle disease control: LaSota or cloned vaccines, looking for ... - The vaccines with respiratory tropism are the LaSota strain-based vaccines or B1 strain vaccines. De...

18. History of the I-2 ND Vaccine - Kyeema Foundation - The commercial poultry industry sponsored the first vaccine trials with the new virus, strain V4. La...

19. Marek's disease: A global challenge to poultry health and productivity - In 1967, Churchill and Biggs (1967) successfully isolated and identified the ... Churchill A.E., Big...

20. Marek's disease-like viruses - Poultry Med - 1967. The agent of Marek's Disease is discovered to be a herpesvirus. Churchill AE, Biggs PM (1967) ...

21. History of the First-Generation Marek's Disease Vaccines - PubMed - During the late 1970s, HVT was no longer fully protective against some new emerging field strains. ....

22. Marek's disease vaccines - Marek's disease (MD) vaccines have been in almost universal use since the early 1970's and constitut...

23. Infectious Bursal Disease in Poultry - Merck Veterinary Manual - Infectious bursal disease was first identified in Gumboro, Delaware, in 1962. ... Inactivated vaccin...

24. History of Gumboro (infectious bursal disease) in Pakistan - PMC - NIH - In Pakistan, first of all this disease was reported in 1971. It is the first review to track the IBD...

25. Maternal antibodies on Infectious Bursal disease vaccines - The use of immune complex vaccines for the prevention of IBD started in about the 1990's. These cons...

26. [PDF] Recombinant Vaccines for Poultry: An Overview of the Basics - An application with the United States Patent and Trademark Office (USPTO) for one of the first recom...

27. [PDF] The History of Infectious Bursal Disease - Soon after the discovery of the antigenic variants, specific commercial vaccines were developed and ...

28. Fifty years of anticoccidial vaccines for poultry (1952-2002) - PubMed - Although earlier investigators experimented with anticoccidial vaccines, the world's first commercia...

29. Influenza viruses and the evolution of avian influenza virus H5N1 - The first clinical respiratory illness of H5N1 avian influenza occurred in Hong Kong in 1997, when 1...

30. Speeding Bird Flu Vaccine Development - Scientific Discoveries - The virus quickly spread across 21 States in 2015, resulting in the loss of 7.5 million turkeys and ...

31. Zoetis Receives Conditional License from USDA for Avian Influenza ... - Zoetis has a long history of developing vaccines to address avian influenza in multiple countries. I...

32. Avian Influenza Vaccine - an overview | ScienceDirect Topics - Avian influenza vaccines are formulated to prevent, manage, or eradicate avian influenza (AI) in pou...

33. Researchers' Egg Vaccines Protect Billions of Chickens

34. In Ovo Vaccination Provides Precise Protection - The first poultry vaccine available for in ovo administration around the world, including Canada, wa...

35. In ovo vaccination technology - PubMed - These studies demonstrate that in ovo vaccination technology using approved vaccine is a safe, effic...

36. Review of Poultry Recombinant Vector Vaccines - PubMed - The control of poultry diseases has relied heavily on the use of many live and inactivated vaccines....

37. The use of vaccines for the control of Salmonella in poultry - By the European Food Safety Authority - This article provides the summary and a link to a paper by t...

38. Vaccines to Control Salmonella in Poultry - Estudio recapitulativo- Vacunas para controlar Salmonella en la avicultura. Esta revisión se centra ...

39. Veterinary Biologics: History and Summary of Activities - USDA-Aphis - Federal regulation of veterinary biologics began in 1913 with passage of the Virus-Serum-Toxin Act. ...

40. History of regulatory requirements for poultry biologics in the United ... - In 1985, Congress passed an amendment to the Virus-Serum-Toxin Act that gave USDA the authority to r...

41. [PDF] History of Regulatory Requirements for Poultry Biologics in the ... - In 1985, Congress passed an amendment to the Virus-Serum-. Toxin Act that gave USDA the authority to...

42. Researchers Explore mRNA Vaccine Technology for Protection ... - USPOULTRY and the USPOULTRY Foundation announce the completion of a research project focused on crea...

43. Fighting Poultry Disease with mRNA: UConn Researchers Pioneer ... - UConn researchers have demonstrated that a novel protein-based nanoparticle can make mRNA vaccines m...

44. New strategies for infectious bronchitis virus vaccine development - Scientists at Pirbright to explore new ways of developing vaccines that can be adapted across strain...